Best stocks · Under $10
Best Stocks Under $10 — Live Top 30 by Tapeline Score
Stocks priced under $10 sit between the penny-stock void and the mid-cap mainstream — a sweet spot of underfollowed names where score-based scoring can still find edge. Tapeline ranks every US ticker under $10 by composite score, filters to 45+ (the lower half of CONSTRUCTIVE), and surfaces the top 30. Cheap names with the trend, fundamentals, or relative strength backing them up.
| # | Ticker | Name | Score | Signal | Price | 1d |
|---|---|---|---|---|---|---|
| 1 | CADL | Candel Therapeutics, Inc. Common Stock | 100 | HIGH CONVICTION | $7.83 | +2.55% |
| 2 | CERS | Cerus Corp | 100 | HIGH CONVICTION | $2.66 | -1.48% |
| 3 | WTI | WTI | 100 | HIGH CONVICTION | $4.74 | — |
| 4 | AURA | Aura Biosciences, Inc. Common Stock | 100 | HIGH CONVICTION | $7.59 | +1.96% |
| 5 | VOXR | VOXR | 100 | HIGH CONVICTION | $5.99 | — |
| 6 | VMD | VMD | 100 | HIGH CONVICTION | $9.62 | — |
| 7 | ARKO | ARKO Corp. Common Stock | 100 | HIGH CONVICTION | $7.22 | -0.42% |
| 8 | ACRS | Aclaris Therapeutics, Inc. | 100 | HIGH CONVICTION | $4.56 | +1.12% |
| 9 | TUSK | TUSK | 100 | HIGH CONVICTION | $3.30 | — |
| 10 | ACDC | ProFrac Holding Corp. Class A Common Stock | 100 | HIGH CONVICTION | $7.96 | -1.37% |
| 11 | SB | SB | 100 | HIGH CONVICTION | $6.84 | — |
| 12 | SATL | SATL | 100 | HIGH CONVICTION | $9.19 | — |
| 13 | OLPX | OLPX | 100 | HIGH CONVICTION | $2.04 | — |
| 14 | KGEI | Kolibri Global Energy Inc. Common Stock | 100 | HIGH CONVICTION | $6.41 | — |
| 15 | BCBP | BCB Bancorp Inc (NJ) | 100 | HIGH CONVICTION | $9.71 | +1.25% |
| 16 | HURA | TuHURA Biosciences, Inc. Common Stock | 100 | HIGH CONVICTION | $2.44 | — |
| 17 | HPK | HighPeak Energy, Inc. Common Stock | 100 | HIGH CONVICTION | $8.18 | — |
| 18 | MCW | Mister Car Wash, Inc. | 100 | HIGH CONVICTION | $7.10 | — |
| 19 | RLGT | RLGT | 100 | HIGH CONVICTION | $8.40 | — |
| 20 | RLJ | RLJ | 100 | HIGH CONVICTION | $9.19 | — |
How the Under $10 ranking works
The Tapeline composite is a transparent weighted sum of six factors: Trend (25%), Relative Strength (20%), Fundamentals (15%), Smart Money (15%), Macro (15%), and Momentum (10%). For the under $10 view, the emphasis is on score + relative strength — but the composite is the better summary signal than any single factor in isolation.
Read the full methodology on /how-it-works, or see how today's picks have performed historically on the public scorecard.
Questions about under $10 on Tapeline
Why $10 as the cutoff?
+
It's the conventional retail dividing line — most brokerages screen 'cheap stocks' at $10, and the cluster of search queries ('best stocks under $10', 'cheap stocks to buy 2026') uses $10 as the anchor. Tapeline matches the convention; the actual edge is composite-score quality within that price band, not the round number.
How is this different from Penny Stocks?
+
Penny stocks (under $5) is a much riskier universe with higher manipulation and bankruptcy rates. Under $10 includes a lot of small- and mid-caps that are simply trading in the $5-$10 range without the deep penny-stock baggage. Score floor here is also higher (45 vs 35) so the surfaced names are higher-quality.
Are there mega-cap stocks under $10?
+
Rarely. Most $10-and-under names are small- to mid-caps, plus the occasional fallen large-cap that hasn't recovered. The Tapeline score is structural — it weighs trend, fundamentals, and macro the same regardless of market cap. So the under-$10 list is mostly small-caps but the scoring lens is consistent.
What if I want to see all cheap stocks, not just the top 30?
+
The live scanner at /app/scanner has full price-range filtering — set min_price/max_price to any range you want, then sort and filter by score, sector, signal label. The list above is an SEO-friendly opinionated view; the scanner is the working tool.
Run this scan live + every other strategy.
14-day Premium trial, no credit card. Full ~2,500-ticker live universe, every sort/filter combination, watchlist + alerts.
Snapshot cached 5 minutes. Sub-60s tick during US market hours. Not investment advice — see risk disclosure.